Literature DB >> 22939863

The role of hepatic metastases and pulmonary tumor burden in predicting survival after complete pulmonary resection for colorectal cancer.

Francesco Sclafani1, Matteo Incarbone, Lorenza Rimassa, Nicola Personeni, Laura Giordano, Marco Alloisio, Armando Santoro.   

Abstract

OBJECTIVE: Our objective was to investigate the role of clinicopathologic factors as predictors of outcome after complete pulmonary resection for metastatic colorectal cancer.
METHODS: Consecutive patients undergoing radical pulmonary resection for colorectal cancer at our institution were included in the study. Clinicopathologic variables including sex, age, site and stage of the primary tumor, disease-free interval, prior hepatic resection, timing of pulmonary metastases, preoperative chemotherapy, type of pulmonary resection, number, size, and location of pulmonary metastases, and thoracic lymph node involvement were retrospectively collected and investigated for prognostic significance. Survival curves were generated by the Kaplan-Meier technique and difference between factors were evaluated by the log-rank test.
RESULTS: A total of 127 patients undergoing pulmonary resection between 1997 and 2009 were included in the study. The median follow-up was 67.1 months. The median overall survival from the time of pulmonary resection was 48.9 months. The 5-year overall survival was 45.4%. Among all investigated prognostic variables, the number of pulmonary metastases (1 vs >1) was the most important factor affecting the outcome after pulmonary resection (5-year overall survival 55.4% vs 32.2%; hazard rate, 1.92; P = .006).
CONCLUSIONS: In this study, the presence of a single pulmonary metastasis was a favorable predictor of survival after complete pulmonary resection for metastatic colorectal cancer. All the other prognostic variables did not seem to affect survival and should not contraindicate such surgery in clinical practice. However, the study sample size does not allow us to draw any definitive conclusion, and further investigation of the role of these prognostic factors in larger series is warranted.
Copyright © 2013 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22939863     DOI: 10.1016/j.jtcvs.2012.07.097

Source DB:  PubMed          Journal:  J Thorac Cardiovasc Surg        ISSN: 0022-5223            Impact factor:   5.209


  5 in total

1.  Lung metastasectomy for postoperative colorectal cancer in patients with a history of hepatic metastasis.

Authors:  Mitsuhiro Kamiyoshihara; Hitoshi Igai; Natsuko Kawatani; Takashi Ibe; Naoki Tomizawa; Kai Obayashi; Kimihiro Shimizu; Izumi Takeyoshi
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-02-08

2.  Does nodal status influence survival? Results of a 19-year systematic lymphadenectomy experience during lung metastasectomy of colorectal cancer.

Authors:  Stéphane Renaud; Marco Alifano; Pierre-Emmanuel Falcoz; Pierre Magdeleinat; Nicola Santelmo; Olivier Pagès; Gilbert Massard; Jean-François Régnard
Journal:  Interact Cardiovasc Thorac Surg       Date:  2014-01-16

3.  Clinical and Radiological Discrimination of Solitary Pulmonary Lesions in Colorectal Cancer Patients.

Authors:  Yoichi Ohtaki; Kimihiro Shimizu; Toshiteru Nagashima; Seshiru Nakazawa; Kai Obayashi; Yoko Azuma; Misaki Iijima; Takayuki Kosaka; Toshiki Yajima; Hiroomi Ogawa; Soichi Tsutsumi; Motohiro Arai; Akira Mogi; Hiroyuki Kuwano
Journal:  World J Surg       Date:  2018-04       Impact factor: 3.352

4.  KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer.

Authors:  S Renaud; B Romain; P-E Falcoz; A Olland; N Santelmo; C Brigand; S Rohr; D Guenot; G Massard
Journal:  Br J Cancer       Date:  2015-02-17       Impact factor: 7.640

5.  KRAS mutation in lung metastases from colorectal cancer: prognostic implications.

Authors:  Michele Ghidini; Nicola Personeni; Silvia Bozzarelli; Marina Baretti; Gianluca Basso; Paolo Bianchi; Maria Chiara Tronconi; Tiziana Pressiani; Fabio Grizzi; Laura Giordano; Alberto Malesci; Marco Alloisio; Luigi Laghi; Armando Santoro; Lorenza Rimassa
Journal:  Cancer Med       Date:  2015-12-29       Impact factor: 4.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.